Informa helps businesses and professionals in hundreds of ways.

Our international portfolio of live events, world-leading research publications, and innovative digital services provide specialists with the knowledge and connections they need to thrive.

Cell & Gene Therapy International Europe
3-5 November 2026
Hotel Palace BerlinBerlin, Germany
Book Now
Menu
Book
Key Sessions
Sarah Snykers
Capacity is No Longer the Limiting Factor of Commercial CAR-T Production, and What Now Determines Commercial Success
Legend Biotech
Gunther Busam
Beyond Manufacturing Scale: Building Sustainable Cell & Gene Therapy Operations
Orchard Therapeutics
keyboard_arrow_right

Wednesday 4th November – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)

keyboard_arrow_leftSearch & Filter
search
Wednesday 4th November – Day 1 Main Conference - GMT (Greenwich Mean Time, GMTZ)
search
Showing 1 of 1 Streams
08:00 - 08:55
Registration & Coffee
Showing 3 of 3 Streams
08:55 - 09:00
Welcome to Cell & Gene Therapy International Europe
  • Catherine Simpson - Conference Director - Cell and Gene Therapy Portfolio, Informa Connect LifeSciences
09:00 - 09:10
Chairperson’s Opening Remarks
09:10 - 09:40
Beyond Manufacturing Scale: Building Sustainable Cell & Gene Therapy Operations
  • Gunther Busam - Vice President, Global Manufacturing Technology and Supply, Orchard Therapeutics
09:40 - 10:30
Keynote Investor Panel: Funding the Future- Investment Trends and Opportunities for Cell and Gene Therapies and Enabling Technologies
  • Bo Wiinberg - Chief Business Development Officer, Novo Nordisk Foundation Cellerator
  • Artemy Shumskiy - Principal, LongeVC
  • Christian Kannemeier - Senior Investment Manager, High-Tech Gründerfonds Management GmbH
  • Ole Henrik Bang-Andreasen - Principal, Avant Bio
  • Gadareth Higgs - Head Healthcare & Life Sciences Partner, Advantary Capital Partners
08:55 - 09:00
Chairperson's Opening Remarks: Exosomes Europe 2026
09:00 - 09:30
KEYNOTE: Novel platform of glycoengineered sEV for superior drug delivery and gene therapy
  • Steffen Goletz, PhD - Full Professor, Head of Biotherapeutic Glycoengineering and Immunology - Institute for Biotechnology & Biomedicine, Danish Technical University
09:30 - 10:00
Cell Line Engineering: Optimising HEK vs. MSC Hubs
  • Bernd Giebel - Founder & CTO, Exosla Therapeutics
10:00 - 10:30
From Bioengineering to Scalable Manufacturing: Advancing Extracellular Vesicles for Targeted Therapeutic Applications
  • Madhusudhan Reddy Bobbili - Universitätsassistent (Assistant Professor), BOKU University
08:55 - 09:00
Chairperson's Opening Remarks: LNPs Europe 2026
09:00 - 09:30
Engineering LNPs for Organ and Cell-Specific Delivery Beyond the Liver
  • Rammohan Devulapally - Sr. Director, Head of Nonviral Delivery, Granza Bio
09:30 - 10:00
Expanding RNA Therapeutics Beyond the Liver: Unlocking New Therapeutic Opportunities with Targeted LNPs
  • Jenny van Asbeck-van der Wijst - CEO, Mercuna BV
10:00 - 10:30
Considerations and Evaluation of LNP Capabilities in Immune Cell Modulation
  • Charlotte Dunne - Senior Research Scientist, Pantherna Therapeutics GmbH
Showing 1 of 1 Streams
10:30 - 11:10
Morning Coffee and Networking Break in Exhibition Hall
Showing 4 of 4 Streams
11:10 - 11:15
Chairperson’s Opening Remarks: Cell Therapy Manufacturing & Analytics
11:15 - 11:45
Capacity is No Longer the Limiting Factor of Commercial CAR-T Production, and What Now Determines Commercial Success
  • Sarah Snykers - Head of Site Strategy & Excellence, Legend Biotech
11:45 - 12:15
Commercialisation of Cell Therapies: Cell Therapy Manufacturing Scale Up from Clinical to Commercial
  • Ketki Flannery - Associate Director MSAT and CMC, Autolous Therapeutics
12:15 - 12:45
From Process Monitoring to Process Intelligence - Building Robust, Scalable Cell Therapy Manufacturing Through Integrated Analytics and Control
  • Sima Hirani - Field Application Scientist, Cell Therapy, Catalent Pharma Solutions
11:10 - 11:15
Chairperson’s Opening Remarks: Gene Therapy Manufacturing & Analytics
11:15 - 11:45
Keynote Panel Discussion: Pioneering Gene Therapy Manufacturing: Tackling Bottlenecks to Scale, Boost Potency, Quality and Lower Costs Per Dose
  • Gunther Busam - Vice President, Global Manufacturing Technology and Supply, Orchard Therapeutics
11:45 - 12:15
Establishing a Network to Produce Lentiviral Vectors for Carvykti®
  • Rutger Douma - MSAT Advanced Therapies Director, Johnson & Johnson Innovative Medicine
12:15 - 12:45
Sponsored Scientific Track Presentation: Implementation of Single Use Technologies for Gene Therapy Manufacturing
11:15 - 11:45
deVINCI: Engineering extracellular vesicles for tissue-selective delivery of genetic medicine
  • Nazma Ilahibaks - CEO & Co-Founder, JAMA Therapeutics
11:45 - 12:15
APN-EV: Stabilising the Functional Form of Adiponectin on Engineered Extracellular Vesicles for Metabolic Disease Therapy
  • Robert Mamoun - CEO, Ciloa
12:15 - 12:45
Managing Bioreactor Dynamics: Mitigating Shear Sensitivity in EV Production
  • Lior Shaltiel - CEO, NurExone Biologic
11:15 - 12:15
Panel Discussion: Targeted Delivery Beyond the Liver – Reformulating LNPs to Achieve Extrahepatic Delivery and Expand Therapeutic Reach
  • Rammohan Devulapally - Sr. Director, Head of Nonviral Delivery, Granza Bio
  • Suzanne Saffie-Siebert - CEO, SiSaf Ltd
12:15 - 12:45
Sponsored Scientific Track Presentation: Pioneering LNP Manufacturing: Tackling Bottlenecks to Scale, Boost Product Quality and Reduce Costs of LNP Process Development and Manufacturing
Showing 2 of 2 Streams
12:45 - 14:00
Networking Lunch in the Exhibition Hall
12:45 - 13:10Live Labs
Networking Lunch in the Exhibition Hall
13:10 - 13:50Live Labs
Live Labs Tour in Exhibition Hall

Gain an insight into some of the most cutting- edge technology and services hitting today’s Cell & Gene Therapies market through a series of 10-minute product demos live at the exhibit booths.


If you are interested in presenting your technology or service as part of the live lab tour please contact Roshni Shah – Roshni.shah@informa.com for more information.

13:50 - 14:00Live Labs
Networking Lunch in the Exhibition Hall
Showing 4 of 4 Streams
14:00 - 14:30
Balancing Personalisation & Scalability in TCR-T Cell Therapies to Scale the Modality
  • Anette Brass - Head of Process Development, Anocca AB
14:30 - 15:00
Quality by Design in Cell Therapy Manufacturing – Implementation of Process Improvements
  • Volker Huppert - Chief Development Officer, Glycostem Therapeutics
15:00 - 15:30
Uncovering the Analytical Iceberg: From Early Uncertainty to Commercial Readiness for Cell Therapy
  • Nicole Lund - Senior Director of Analytical & Quality Control, BlueRock Therapeutics
14:00 - 14:30
Upstream Innovation to Improve Product Quality and Increase Cell Density in Scalable AAV Production
  • Clotilde Ciesla - Upstream Development Engineer, Genethon
14:30 - 15:00
Cell-Free AAV Manufacturing: Redefining Scalability, Quality, and Cost in Gene Therapy
  • Jordan Turnbull - Co-Founder, Co-CEO, CSO, Fuse Vectors
15:00 - 15:30
Case Study from VectorY: Revolutionising Large Scale Gene Therapy Production
  • Jelmer Willems - Senior Scientist, Group leader, Vector Development, VectorY
14:00 - 14:30
A roadmap to develop potency assay for EV-based product
  • Rajeev Tawar - Associate Director, Vector and Analytical Development, Evox Therapeutics
14:30 - 15:00
Engineering Targeted Extracellular Vesicles for Translational Drug Delivery
  • Alena Ivanova - Senior Scientist, AstraZeneca
15:00 - 15:30
[Clinical Case Study] Targeted by Nature, Powered by Innovation: EXO-CD24 Is Pioneering a New Class of Exosome-Based Therapies
  • Shiran Shapira - CTO/CSO, Nano24
14:00 - 14:05
Chairperson's Opening Remarks
  • Christian Reinsch - Vice President Technology Profiling, BioNTech SE
14:05 - 14:35
Unpacking LNPs: A Practical Overview of Innovative Analytical Technologies for LNP Characterisation
  • Sébastien Wang - Responsable R&D, Silon Therapeutics
14:35 - 15:05
Innovative Analytics and Characterisation Strategies for LNPs
  • Chuan-En Lu - Senior Scientist, AstraZeneca
15:05 - 15:35
Sponsored Scientific Track Presentation: Integrating PAT Technologies and Process Analytics for LNP Manufacturing Process Monitoring and Quality Control
Showing 1 of 1 Streams
15:35 - 16:20
Afternoon Coffee and Networking Break in Exhibition Hall
Showing 4 of 4 Streams
16:20 - 16:50
Cell Therapy Reimagined: The Science of Continuous Improvement in Quality and Performance
  • Ramiz Saramati - QA Operations Expert, Novartis
16:50 - 17:20
End to End Workflow Automation in Cell Therapy Manufacturing: Strategies for Implementation at Scale
16:20 - 16:50
From Bottlenecks to Breakthroughs: Driving Innovation in AAV Downstream Processing for Speed, Scale, and Sustainability
  • Parag Kumthekar - Lead Gene Therapy Downstream Process Development, UCB
16:20 - 17:20
Where Are Extracellular Vesicles Headed? Mapping the Future of EV Therapeutics from Lab Curiosity to Approved Class
  • What is the single biggest milestone the exosome field must achieve by 2028 to maintain investor and pharma confidence?
  • Native secretomes vs. engineered targeted vesicles: Which path crosses the clinical finish line first?
  • Learning from the cell therapy playbook: How do we avoid the 20-year translational lag that plagued early MSCs?
  • What will finally convince Big Pharma to commit to major licensing deals?
  • Defining convincing clinical endpoints when exosome therapeutics operate across multiple biological mechanisms at once.
16:20 - 16:50
Regulatory Feedback – Navigating the Evolving Regulatory Landscape for LNPs
  • Ka-Wai Wan - Expert Pharmaceutical / Quality Assessor, MHRA
17:20 - 18:30
Networking Drinks Reception in the Exhibition Hall
Tuesday 3rd November – Pre-Conference Workshops
NextThursday 5th November – Day 2 Main Conference
Filter
Streams
Choose Day